Cardiac Death After TAVR Moving Up a Notch∗ by Lefèvre, Thierry
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 5 , N O . 5 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 1 1 . 0 2 6EDITORIAL COMMENTCardiac Death After TAVR
Moving Up a Notch*Thierry Lefèvre, MDT he paper by Urena et al. (1) in this issue of theJournal deserves our most careful attention.Now that transcatheter aortic valve implan-
tation (TAVI) has reached relative maturity in terms
of equipment, technical strategy, and screening
reﬁnement, and given that eligibility of patients at in-
termediate risk is increasingly envisioned (2), this
investigation of predictors of mid-term cardiac death
via a large, international, multicenter trial conducted
in the real world was timely.SEE PAGE 437Since Alain Cribier’s ﬁrst procedure in 2012 (3),
considerable progress has been made with respect to
procedural success and 30-day mortality rates.
Whereas 30-day mortality was as high as 15% to 30%
earlier, it is currently around 2% to 5%. This is
attributable to several factors: enhanced screening,
which allows for improved patient selection while
discarding futile indications; better valve sizing
thanks to aortic annulus measurement by multislice
computed tomography; and the introduction of
3-dimensional echocardiography. Improved device
deliverability and safety, lower introducer proﬁle,
and pooling and sharing of practical operator expe-
rience and knowledge have also translated into better
acute outcomes and efﬁcient management of poten-
tial complications.
In the PARTNER (Placement of Aortic Trans-
catheter Valves) trial, transcatheter aortic valve
replacement (TAVR) was associated with a very sig-
niﬁcant improvement in the survival of patients*Editorials published in the Journal of the American College of Cardiology
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views of JACC or the American College of Cardiology.
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ment. However, despite the valve’s very good he-
modynamic performance, a sizable proportion of
patients (around 25%) died during the year following
the procedure (4,5). This prompted a better selection
of indications (PARTNER Cohort C) (6), which
decreased overall mortality, but only modestly
reduced the cardiac-related death rate.
The main focus of the study by Urena et al. (1) was
cardiac-related death and potential strategies for its
reduction. This large study analyzed the outcomes of
3,726 patients on the basis of prospective data
collected in 18 centers worldwide with broad experi-
ence in TAVI. These patients were treated in a real-
life setting, evidenced by their mean age (81 years)
and relatively low logistic EuroSCORE (19.4%)
compared with the PARTNER trial (29%). The patients
also had numerous comorbidities such as: diabetes
(30%); chronic obstructive pulmonary disease (26%);
paroxysmal or permanent atrial ﬁbrillation (30%);
coronary disease (54%); and #40% ejection fraction
(EF) (15%). Use of either a balloon- or a self-
expandable valve (57% vs. 43%) was standard prac-
tice in Europe, as was the transfemoral approach,
which was implemented in most cases (79.7%), with
the transapical route as the main alternative (16.3%).
All-cause mortality was 7.8% at 30 days and 27.4%
at a mean follow-up of 22 months. Cardiovascular
death accounted for 65% of all-cause mortality, with
one-half solely cardiac-related (50% cardiac failure
and 17% sudden cardiac death). A considerable per-
centage of cardiovascular mortality was associated
with procedure-related cardiac complications (11.3%)
and other procedure-related complications (24.6%).
Three factors may be essential for improving
TAVI outcomes. The most simple and obvious are
procedure-related (6-8). Improvements in patient
screening, equipment, and implantation techniques
should allow procedure-related mortality, which ac-
counts for 35.9% of all cardiovascular deaths in this
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450series, to continuously decrease. An analysis of the
effect of center experience on 30-day outcomes would
have provided additional valuable information.
The second factor is cardiac death from advanced
heart failure, a key element of this study (1), which
highlighted predictors associated with the risk of
death from heart failure. Some, such as chronic
obstructive pulmonary disease (hazard ratio [HR]:
1.6) or the presence of permanent or paroxysmal atrial
ﬁbrillation (HR: 2.3), severe pulmonary hypertension
(HR: 2.0), or a low aortic gradient, are risk markers.
Other parameters are potentially controllable, such as
the transapical approach (HR: 2.4) or post-procedural
aortic regurgitation >1 grade (HR: 2.8). Paravalvular
leak was controversial for many years. However,
these data support a robust assumption regarding
TAVR (9), which was already veriﬁed in patients un-
dergoing conventional surgical valve replacement
(10). It is also very interesting that following TAVR,
the risk of death from heart failure triples in patients
with grade >1 aortic regurgitation combined with
severe pulmonary hypertension at baseline.
Conversely, as demonstrated in earlier studies
(11,12), pre-procedural aortic regurgitation>1 confers a
protective effect in cases of grade >1 aortic regurgita-
tion following TAVR. The excess risk associated with
the transapical approach versus the transfemoral route
had long been controversial because patients under-
going transapical TAVIwere older, had a higher logistic
EuroSCORE or Society of Thoracic Surgeons score, and
had a higher rate of comorbidities (13). However, this
route is more aggressive (14,15), requiring general
anesthesia, opening of the pleura and pericardium,
myocardial damage at the level of the puncture site,
and causing post-procedural thoracic pain, which
generates extra discomfort and slows recovery. The
PARTNER II and France II studies (16,17) demonstrated
that the transapical route was independently associ-
ated with excess risk, which Urena et al. (1) conﬁrmed
by conducting the largest analysis of this issue to date.
The third element of interest involves the risk
(although relatively low [6% of all deaths; 17% of
cardiac-related deaths] of sudden death after TAVR.
Of 2 sudden death–associated factors, left bundle-
branch block [LBBB] at discharge, with an HR of 2.2
for death, can be modiﬁed. The other, EF #40%, isboth an independent and an aggravating factor, with
an HR of 2.1, rising to 12.3 when both factors are
combined. In patients who experienced LBBB after
TAVI, the only predictor of sudden death on the
electrocardiogram was >160 ms QRS width at
discharge. Unfortunately, although the risk factor
was 3.1, no signiﬁcant differences were observed in
the survival rate, whether or not patients received a
prophylactic pacemaker (PM) (HR: 3.13, 95% conﬁ-
dence interval: 0.38 to 25.63). This could be attrib-
uted to the small number of patients (2.5% of the
study population) and also to potential inclusion
bias. The controversy is, therefore, unlikely to be
resolved with respect to the indication for a prophy-
lactic PM, or even deﬁbrillation with resynchroniza-
tion, especially in patients experiencing LBBB with
>160 ms QRS width with #40% EF. Let us hope that
the MARE (Ambulatory Electrocardiographic Moni-
toring for the Detection of High-Degree Atrio-Ven-
tricular Block in Patients With New-onset PeRsistent
LEft Bundle Branch Block After Transcatheter Aortic
Valve Implantation) trial (18) provides a satisfactory
answer. An additional means of controlling the risk of
a large LBBB is to implant the valve in a high posi-
tion, limiting the risk of damaging the conduction
tissue.
Beyond technical achievements, the paper by
Urena et al. (1) sheds useful light on the risk of
mortality from cardiac failure after TAVR, which,
although substantial, is not ineluctable. Indeed, we
can control 3 key factors: 1) selection of the trans-
femoral route whenever feasible and safe; 2) pre-
vention of the occurrence of paravalvular leak >1
grade by optimal valve sizing and positioning and its
correction by adequate post-dilation (19), a problem
that newer-generation valves will probably solve; and
3) consideration of systematic PM implantation, or
even resynchronization, in the presence of an LBBB
with large QRS width (>160 ms) for patients with
signiﬁcantly impaired left ventricular function.
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